Update on pathobiology in Stevens-Johnson syndrome and toxic epidermal necrolysis

Dermatologica Sinica

Volumn 31, Issue 4, 2013, Pages 175-180

  Su, Shih Chi ^a   Chung, Wen Hung ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

drug hypersensitivity; human leukocyte antigens; Stevens Johnson syndrome; toxic epidermal necrolysis

Indexed keywords

ALLOPURINOL; ANTICONVULSIVE AGENT; CARBAMAZEPINE; FAS ANTIGEN; FAS LIGAND; GRANULYSIN; GRANZYME B; LAMOTRIGINE; METHAZOLAMIDE; OXCARBAZEPINE; OXICAM DERIVATIVE; PERFORIN; PHENYTOIN; SULFAMETHOXAZOLE; SULFONAMIDE;

ALLELE; CELL DEATH; CYTOTOXIC T LYMPHOCYTE; DRUG HYPERSENSITIVITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GEOGRAPHIC DISTRIBUTION; HLA SYSTEM; HUMAN; IMMUNE RESPONSE; KERATINOCYTE; MORBIDITY; MORTALITY; NATURAL KILLER CELL; PATHOGENESIS; PATHOLOGY; REVIEW; STEVENS JOHNSON SYNDROME; T LYMPHOCYTE ACTIVATION; TOXIC EPIDERMAL NECROLYSIS;

EID: 84887321022     PISSN: 10278117     EISSN: 2223330X     Source Type: Journal    
DOI: 10.1016/j.dsi.2013.09.002     Document Type: Review

References (71)

1. J.C. Roujeau, and R.S. Stern Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
2. P. Paquet, G.E. Pierard, and P. Quatresooz Novel treatments for drug-induced toxic epidermal necrolysis (Lyell's syndrome) Int Arch Allergy Immunol 136 2005 205 216
3. K.C. Wong, P.J. Kennedy, and S. Lee Clinical manifestations and outcomes in 17 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis Austrialas J Dermatol 40 1999 131 134
4. V.N. Sehgal, and G. Srivastava Toxic epidermal necrolysis (TEN) Lyell's syndrome J Dermatolog Treat 16 2005 278 286
5. J.M. Mulvey, A. Padowitz, and M. Lindley-Jones Mycoplasma pneumoniae associated with Stevens Johnson syndrome Anaesth Intensive Care 35 2007 414 417
6. R. Forman, G. Koren, and N.H. Shear Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience Drug Saf 25 2002 965 972
7. M. Mockenhaupt, C. Viboud, and A. Dunant Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study J Invest Dermatol 128 2008 35 44
8. J.C. Roujeau, J.P. Kelly, and L. Naldi Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis N Engl J Med 333 1995 1600 1607
9. B. Rzany, O. Correia, and J.P. Kelly Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions Lancet 353 1999 2190 2194
10. E. Letko, D.N. Papaliodis, and G.N. Papaliodis Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of the literature Ann Allergy Asthma Immunol 94 2005 419 436 quiz 436-8, 456
11. L.E. French Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding Allergol Int 55 2006 9 16
12. B. Rzany, M. Mockenhaupt, and S. Baur Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry J Clin Epidemiol 49 1996 769 773
13. K.E. Ward, R. Archambault, and T.L. Mersfelder Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature Am J Health Syst Pharm 67 2010 206 213
14. F.A. Pereira, A.V. Mudgil, and D.M. Rosmarin Toxic epidermal necrolysis J Am Acad Dermatol 56 2007 181 200
15. A.T. Borchers, J.L. Lee, and S.M. Naguwa Stevens-Johnson syndrome and toxic epidermal necrolysis Autoimmun Rev 7 2008 598 605
16. B.R. Del Pozzo-Magana, A. Lazo-Langner, and B. Carleton A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children J Popul Ther Clin Pharmacol 18 2011 e121 e133
17. J.S. Prendiville, A.A. Hebert, and M.J. Greenwald Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children J Pediatr 115 1989 881 887
18. B.L. Strom, J.L. Carson, and A.C. Halpern A population-based study of Stevens-Johnson syndrome. Incidence and antecedent drug exposures Arch Dermatol 127 1991 831 838
19. J.P. Fagot, M. Mockenhaupt, and J.N. Bouwes-Bavinck Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis Aids 15 2001 1843 1848
20. N. Mittmann, B.C. Chan, and S. Knowles IVIG for the treatment of toxic epidermal necrolysis Skin Therapy Lett 12 2007 7 9
21. S. Fournier, S. Bastuji-Garin, and H. Mentec Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection Eur J Clin Microbiol Infect Dis 14 1995 558 559
22. R. Mandelcorn, and N.H. Shear Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol 48 2003 525 529
23. Y. Aihara, S. Ito, and Y. Kobayashi Stevens-Johnson syndrome associated with azithromycin followed by transient reactivation of herpes simplex virus infection Allergy 59 2004 118
24. J.L. Zakrzewski, G. Lentini, and U. Such Toxic epidermal necrolysis: differential diagnosis of an epidermolytic dermopathy in a hematopoietic stem cell transplant recipient Bone Marrow Transplant 30 2002 331 333
25. L.R. Pohl, H. Satoh, and D.D. Christ The immunologic and metabolic basis of drug hypersensitivities Annu Rev Pharmacol Toxicol 28 1988 367 387
26. E. Padovan, T. Bauer, and M.M. Tongio Penicilloyl peptides are recognized as T cell antigenic determinants in penicillin allergy Eur J Immunol 27 1997 1303 1307
27. W.J. Pichler Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept Curr Opin Allergy Clin Immunol 2 2002 301 305
28. T.M. Ko, W.H. Chung, and C.Y. Wei Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome J Allergy Clin Immunol 128 2011 1266 1276 e11
29. C.Y. Wei, W.H. Chung, and H.W. Huang Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome J Allergy Clin Immunol 129 2012 1562 1569 e5
30. P.T. Illing, J.P. Vivian, and N.L. Dudek Immune self-reactivity triggered by drug-modified HLA-peptide repertoire Nature 486 2012 554 558
31. D.A. Ostrov, B.J. Grant, and Y.A. Pompeu Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire Proc Natl Acad Sci U S A 109 2012 9959 9964
32. M.A. Norcross, S. Luo, and L. Lu Abacavir induces loading of novel self-peptides into HLA-Bâ̂ - 57: 01: an autoimmune model for HLA-associated drug hypersensitivity Aids 26 2012 F21 F29
33. J.C. Roujeau, T.N. Huynh, and C. Bracq Genetic susceptibility to toxic epidermal necrolysis Arch Dermatol 123 1987 1171 1173
34. W.H. Chung, S.I. Hung, and H.S. Hong Medical genetics: a marker for Stevens-Johnson syndrome Nature 428 2004 486
35. C.B. Man, P. Kwan, and L. Baum Association between HLA-Bâ̂ - 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese Epilepsia 48 2007 1015 1018
36. C. Locharernkul, J. Loplumlert, and C. Limotai Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-Bâ̂ - 1502 allele in Thai population Epilepsia 49 2008 2087 2091
37. T.Y. Mehta, L.M. Prajapati, and B. Mittal Association of HLA-Bâ̂ - 1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians Indian J Dermatol Venereol Leprol 75 2009 579 582
38. S.H. Kim, K.W. Lee, and W.J. Song Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans Epilepsy Res 97 2011 190 197
39. A. Alfirevic, A.L. Jorgensen, and P.R. Williamson HLA-B locus in Caucasian patients with carbamazepine hypersensitivity Pharmacogenomics 7 2006 813 818
40. N. Kaniwa, Y. Saito, and M. Aihara HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis Pharmacogenomics 9 2008 1617 1622
41. S.I. Hung, W.H. Chung, and L.B. Liou HLA-Bâ̂ - 5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol Proc Natl Acad Sci U S A 102 2005 4134 4139
42. W. Tassaneeyakul, T. Jantararoungtong, and P. Chen Strong association between HLA-Bâ̂ - 5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population Pharmacogenet Genomics 19 2009 704 709
43. H.R. Kang, Y.K. Jee, and Y.S. Kim Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans Pharmacogenet Genomics 21 2011 303 307
44. C. Lonjou, N. Borot, and P. Sekula A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs Pharmacogenet Genomics 18 2008 99 107
45. T. Ozeki, T. Mushiroda, and A. Yowang Genome-wide association study identifies HLA-Aâ̂ - 3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population Hum Mol Genet 20 2011 1034 1041
46. M. McCormack, A. Alfirevic, and S. Bourgeois HLA-Aâ̂ - 3101 and carbamazepine-induced hypersensitivity reactions in Europeans N Engl J Med 364 2011 1134 1143
47. N. Kaniwa, Y. Saito, and M. Aihara HLA-Bâ̂ - 1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients Epilepsia 51 2010 2461 2465
48. S.I. Hung, W.H. Chung, and S.H. Jee Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions Pharmacogenet Genomics 16 2006 297 306
49. S.I. Hung, W.H. Chung, and Z.S. Liu Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese Pharmacogenomics 11 2010 349 356
50. S.H. Kim, M. Kim, and K.W. Lee HLA-Bâ̂ - 5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis Pharmacogenomics 11 2010 879 884
51. I. Viard, P. Wehrli, and R. Bullani Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin Science 282 1998 490 493
52. I. Viard-Leveugle, R.R. Bullani, and P. Meda Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions J Biol Chem 278 2003 16183 16188
53. P. Paquet, and G.E. Pierard Keratinocyte injury in drug-induced toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin Int J Mol Med 10 2002 145 147
54. A. Nassif, H. Moslehi, and S. Le Gouvello Evaluation of the potential role of cytokines in toxic epidermal necrolysis J Invest Dermatol 123 2004 850 855
55. R. Abe, T. Shimizu, and A. Shibaki Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand Am J Pathol 162 2003 1515 1520
56. M. Bots, and J.P. Medema Granzymes at a glance J Cell Sci 119 2006 5011 5014
57. K. Veugelers, B. Motyka, and I.S. Goping Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate Mol Biol Cell 17 2006 623 633
58. S.J. Posadas, A. Padial, and M.J. Torres Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity J Allergy Clin Immunol 109 2002 155 161
59. A. Nassif, A. Bensussan, and G. Dorothee Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis J Invest Dermatol 118 2002 728 733
60. W.H. Chung, S.I. Hung, and J.Y. Yang Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis Nat Med 14 2008 1343 1350
61. R. Abe, N. Yoshioka, and J. Murata Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome Ann Intern Med 151 2009 514 515
62. A. Deng, S. Chen, and Q. Li Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator J Immunol 174 2005 5243 5248
63. A. Nassif, A. Bensussan, and L. Boumsell Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells J Allergy Clin Immunol 114 2004 1209 1215
64. C.W. Wang, W.H. Chung, and Y.F. Cheng A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders J Allergy Clin Immunol 132 2013 713 722
65. P. Paquet, F. Paquet, and W. Al Saleh Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis Am J Dermatopathol 22 2000 413 417
66. O. Correia, L. Delgado, and I.L. Barbosa Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis J Am Acad Dermatol 47 2002 58 62
67. B. Tapia, A. Padial, and E. Sanchez-Sabate Involvement of CCL27-CCR10 interactions in drug-induced cutaneous reactions J Allergy Clin Immunol 114 2004 335 340
68. M. Caproni, D. Torchia, and E. Schincaglia Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis Br J Dermatol 155 2006 722 728
69. H. Ikeda, Y. Takahashi, and E. Yamazaki HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions Epilepsia 51 2010 297 300
70. H. Niihara, T. Kakamu, and Y. Fujita HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population J Dermatol 39 2012 594 601
71. G.R. Kazeem, C. Cox, and J. Aponte High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients Pharmacogenet Genomics 19 2009 661 665